2 chapters across the catalog
Pfizer Pseudovirus, Omicron Specific Vaccine Development
Pfizer CEO Albert Bourla discusses the development of an Omicron-specific vaccine using a "pseudovirus" constructed in a laboratory. The hosts question why a synthetic version of the virus is used for testing rather than a natural isolate.
Pfizer and Moderna Omicron Vaccine Marketing Strategies
Pharmaceutical CEOs from Pfizer and Moderna are criticized for aggressively marketing booster shots in response to the Omicron variant. Pfizer CEO Albert Bourla admitted on CNBC that current data relies on a "pseudovirus" constructed in a lab rather than real-world samples. The narrative suggests that the industry is pivoting toward a three-dose or four-dose requirement before comprehensive clinical data is available.
